Health

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA ...

2024-05-10 12:16 887

SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer

SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 ...

2024-05-10 12:00 575

Diagnostic Imaging for Women Enhances Mammography Quality with AI: Results Presented at ASMIRT 2024

DARWIN, Australia, May 10, 2024 /PRNewswire/ -- At the Australian Society of Medical Imaging and Radiation Therapy (ASMIRT) conference this week in Darwin, Diagnostic Imaging for Women (difw), together with Volpara Health announced significant advancements in applying AI to mammography quality as...

2024-05-10 08:58 743

Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost

* Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) * Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- CelltrionUSA announced today that adalimumab-aa...

2024-05-10 07:41 600

Origin Agritech Receives GMO Safety Certificate for its Triple Stack Maize

Commercial Rollout to Begin Shortly BEIJING, May 9, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced the issuance of a GMO safety certificate for its transgenic maize, BBL2-2, marking a signif...

2024-05-09 20:30 770

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias. Preliminary data of VCAS study will be presented at HRS 2024 in Boston, Mass. CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field M...

2024-05-09 20:03 983

FDA Clears the Individualized Nomogram for Rika Plasma Donation System

The latest innovation is anticipated to increase collection volume without increasing collection time * Rika's individualized nomogram, iNomi, can enable plasma donors to donate the right amount of plasma on any given day based on height, weight and hematocrit. * The Rika Plasma Donation Sys...

2024-05-09 20:00 642

Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines

Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in pr...

2024-05-09 15:30 837

Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines

Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in pr...

2024-05-09 15:30 855

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

TAIPEI, May 9, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), for exclusive rights to the commercialization of clobetasol...

2024-05-09 15:00 1088

Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions

TOKYO, May 9, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2  The GHIT Fund inv...

2024-05-09 10:00 943

Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints

SAN FRANCISCO and SUZHOU, China, May 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, o...

2024-05-09 08:00 1121

TraceLink Named to 2024 RXinsider Pharmacy500 List

BOSTON, May 9, 2024 /PRNewswire/ -- TraceLink, a leader in end-to-end digital supply chain solutions, is proud to announce its inclusion in the Pharmacy500 list for 2024 by RXinsider. This recognition places TraceLink among the most impactful pharmacy supply chain companies inthe United States, a...

2024-05-09 00:53 719

Registration opens for Medtec China 2024

BEIJING, May 9, 2024 /PRNewswire/ -- According to the report of China Federation of Logistics & Purchasing (CFLP), the market size of China's medical device sector reachedRMB 1,250 billion in 2023, with a growth rate 2.4 times faster than that of the global medical device industry. To Vigorously ...

2024-05-09 00:00 631

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024. This year's event included 1,000 registered attendees from all over the glob...

2024-05-08 23:25 537

Front Street Re Appoints Edison Fong as Chief Executive Officer

GEORGETOWN, Cayman Islands, May 8, 2024 /PRNewswire/ -- Front Street Re  ("FSR" or the "Company"), an international Insurtech and reinsurance company that focuses on annuity, life, health, and general reinsurance solutions and is an operating subsidiary ofLexasure Fin...

2024-05-08 21:22 646

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer inAustralia in t...

2024-05-08 21:00 942

Waters ACQUITY QDa II Mass Detector Delivers Wider Range of Chemical Analysis within Cost-Effective, Lower Energy Instrument

News Summary: * ACQUITY™ QDa™ II Mass Detector enhances confidence in routine compound identification using the specificity of mass analysis to boost efficiency, robustness, and productivity in LC-UV separations, while leveraging the Empower™ Chromatography Data System for complete traceabilit...

2024-05-08 20:40 825

Körber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking

LONDON, May 8, 2024 /PRNewswire/ -- The new Competitive Assessment by global technology intelligence firmABI Research provides an in-depth and unbiased examination of the solutions offered by 13 manufacturing execution system (MES) software suppliers targeting pharmaceutical, biotech, and cell & ...

2024-05-08 20:30 822

TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg)  * Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain re...

2024-05-08 20:00 672
12345 ... 821